Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Key topics
COVID-19
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Publications
Filters:
Biosimilar medicines
x
policy
x
By group
By type
External Resources
Factsheets
Infographics
PODCAST
Policy
Reports
Videos
Newsroom
Twitter
Tweets
Videos
Photos
Safe Prescription,Safe Dispensing, Identification and Track&Trace of All Biologicals in the Context of the Re-opened Biosimilars INN Debate – 11th EGA Symposium on Biosimilar Medicines, Suzette Kox, London 2013
25 April 2013
Policy
Read More
Biosimilar Monoclonal Antibodies – 11th EGA International Symposium on Biosimilar Medicines, Gudbjorg Edda Eggertsdottir, London, 25 April 2013
25 April 2013
Policy
Read More
Production and Control of Biosimilars versus Innovators, Biosimilars Present and Future – Da Silva, Infarmed, Lisbon, 3 April 2013 (PPT)
3 April 2013
Policy
Read More
Emergence of Biosimilar Medicines – The Biosimilar Company Point of View, Paul Greenland, Belgium Federal Parliament, Brussels, 22 November 2012 (PPT)
22 November 2012
Policy
Read More
EMA Questions and Answers on Biosimilar Medicines (Similar Biological Medicinal Products)
27 September 2012
Policy
Read More
Posts navigation
1
…
3
4
5
Subscribe to our newsletter
Medicines For Europe
Who we are
Key topics
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn